Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Dear Christopher This information (below) may be helpful to you
Document related concepts
no text concepts found
Transcript
Dear Christopher This information (below) may be helpful to you. The drug costs for the treatment of inpatients in one ward at xxxxxxxxxx Hospital with neutropenia (probably almost all with sepsis) are below. We estimate that there were 193 patients with that diagnosis during that 12 month period. Note that we only use GCSF for patients with toxic shock and that the Chief Pharmacist thinks that the total cost is probably and underestimate. Since the mean drug cost appears to be only £355 per patient, it does seem low. Yours xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx From: xxxxxxxxxxxxx Sent: 09 October 2007 08:29 To: xxxxxxxxxxxxxx Subject: RE: Single Technology Appraisal: Erlotinib for the treatment of non-small cell lung cancer Costing as follows 1/10/06 to 30/9/07 Filgrastim (treatment) £12,800 Ciprofloxacin 750mg £96 Co-Amoxiclav 625mg £2076 Gentamicin £2723 Tazocin £48,498 Imipenen £1160 Total £67,353 This is probably an underestimation Sian From: xxxxxxxxxxx Sent: 08 October 2007 11:53 To: xxxxxxxxxx Subject: RE: Single Technology Appraisal: Erlotinib for the treatment of non-small cell lung cancer Thanks xxxxxxx – I would be grateful if you could do some costings for them. xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx From: xxxxxxxxxx Sent: 05 October 2007 13:46 To:xxxxxxxxxxxxxxx Subject: RE: Single Technology Appraisal: Erlotinib for the treatment of non-small cell lung cancer Our policy is not to use gcsf for TREATMENT of Neutropenia, unless the patient is in shock. Most of our use is for secondary prophylaxis. I can find out what has been issued to PMW as stock and assume that is for treatment. The main drug cost in treatment of neutropenia would be for Tazocin, Gentamicin and some oral antibiotics, mainly Ciprofloxacin and Augmentin. I could do an estimate for these but it would not be accurate. xxxxxxxx and xxxxxxxxxxxxx were looking at compliance to the neutropenia policy last year and may have some figures xxxxxxxx From:xxxxxxxxxxxxxxx Sent: 05 October 2007 09:50 To: xxxxxxxxxxx Subject: FW: Single Technology Appraisal: Erlotinib for the treatment of non-small cell lung cancer See the letter below from NICE. Do we have any general (not docetaxel specific) figures about the use of GCSF in neutropenic patients in xxxxxxxxxxxxx? xxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Related documents